10 May 2017 in Journal of the Chinese Medical Association
Superior vena cava (SVC) syndrome comprises a group of signs and symptoms secondary to SVC obstruction. Obstruction occurs when venous return from the SVC to the right atrium is compromised, mostly by a growing malignancy compressing the SVC extrinsically.1, 2, 3, 4, 5 In the absence of adequate collaterals, the resulting elevated venous pressure in the upper body leads to edema of the head, neck, and upper extremities. Rarely, swelling of the larynx may cause life-threatening airway obstruction and cerebral edema, which can result in confusion and coma. While treatment of underlying malignant disease is paramount, it may be slow to alleviate the patient's discomfort. In some radiosensitive malignancies, radiotherapy may effectively reduce symptoms by reducing the tumor size,3, 6 but this process can take weeks to months and has a higher recurrence rate. The increasing technical and clinical success rate of SVC stenting makes it another option for salvage therapy after conventional radiochemotherapy has failed. In fact, Ganeshan et al. suggested that primary SVC stenting should be the first-line treatment to relieve the symptoms of SVC syndrome.4 The aim of the present study was to review our SVC stenting experience retrospectively in order to validate the safety, effectiveness, and outcomes of salvage and primary stenting for malignant SVC obstruction.
21 December 2020 in Interactive CardioVascular and Thoracic Surgery
OBJECTIVES: Although commercial iliac branch devices offer a new and valid endovascular approach to treating iliac aneurysm and effectively preserve antegrade flow of the internal iliac artery, their use may not be suited for all types of challenging anatomy, especially isolated common iliac artery aneurysm. Our custom-made iliac bifurcation device has a unique design and excludes both combined and isolated iliac branch aneurysm. This study validated the efficacy and safety of the custom device by comparing clinical outcomes between groups receiving commercial and custom devices. METHODS: Data of consecutive patients receiving iliac bifurcation device implantation for iliac aneurysm with or without concomitant endovascular repair for abdominal aortic aneurysm from January 2010 to May 2019 were reviewed. RESULTS: Iliac bifurcation device implantation with or without concomitant abdominal aortic aneurysm stent grafting was completed in 46 patients (commercial, n = 35; custom, n = 11). No significant differences were observed regarding postoperative complications, occlusion or endoleak. Comparisons of primary (80.8% vs 85.7%, P = 0.88) and secondary (86.5% vs 85.7%, P = 0.85) patency and freedom from reintervention (88.2% vs 100%, P = 0.33), all-cause mortality (78.6% vs 100%, P = 0.25) and aneurysm-related mortality (100% vs 100%, P = 1.00) also indicated no differences at a 5-year surveillance point. Furthermore, the iliac aneurysms of the groups displayed similar shrinkage 1 year after procedures. CONCLUSIONS: For iliac aneurysm, the novel custom-made iliac bifurcation device is an adaptable design not inferior to commercial devices with regard to postoperative complications, bridge occlusion, endoleak and short-term aneurysm remodelling. It provides an alternative for treatment, particularly when certain anatomic challenges are present. Clinical trial registration: 2018-07-050BC, 2017-01-023ACF.
1 July 2019 in Journal of Vascular and Interventional Radiology
7 March 2023 in Journal of Cardiothoracic Surgery
Pump exchange surgery of left ventricular assist device (LVAD) has been demonstrated in several studies; however, information for Asian patients was limited. A 63-year-old man underwent a pump upgrade from HeartMate II to HeartMate 3 for driveline damage through limited left anterior thoracotomy and lower partial sternotomy. He did not experience any hemodynamic adverse events or device malfunction during postoperative follow-ups of 12 months. We also reviewed all published cases with HeartMate II exchange to HeartMate 3. The case demonstrated that it was safe and feasible to perform HMII LVAD exchange to HM3 through a limited approach for Asian patients.
1 July 2024 in Quantitative Imaging in Medicine and Surgery
Background: No recommendations have been made regarding the puncture position during tunnelled dialysis catheter (TDC) insertion from right internal jugular vein (RIJV). We investigated the effect of puncture positioning along with other characteristics and clinical factors associated with TDCs to determine their correlation with catheter patency rate. Methods: We retrospectively reviewed TDC insertion procedures performed between January 2018 and December 2020 at a single institution. Patients were monitored for at least 1 year or until TDC removal or replacement. The distance on the post-operative chest radiography were measured to determine the height of puncture position. End points were freedom from catheter dysfunction. Results: Total 949 catheters met the eligibility criteria. Catheter dysfunction occurred in 233 patients and catheter infection in 127 patients. By multivariate analysis, female sex [hazard ratio (HR) =1.497, 95% confidence interval (CI): 1.119–2.002; P=0.007] and split-tip catheter (HR =1.453, 95% CI: 1.087–1.944; P=0.012) were associated with an increased rate of catheter dysfunction. Every 10-year increment in age (HR =1.243, 95% CI: 1.123–1.376; P<0.001) and every 1-cm increase in the height of the catheter insertion site (HR =1.270, 95% CI: 1.096–1.473; P=0.001) were also associated with an increased rate of catheter dysfunction. After classifying the height of puncture position into 3 groups, significant worse patency was observed in the catheter with puncture height more than 4 cm (P=0.025). No immediate complications were observed. Conclusions: TDC insertion at a high puncture site correlates with an increased risk of catheter dysfunction. Puncturing the RIJV close to the clavicle is safe and enhances catheter patency.